1. Home
  2. AIOS vs ARTL Comparison

AIOS vs ARTL Comparison

Compare AIOS & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIOS

AIOS Tech Inc. Class A Common Shares

N/A

Current Price

$18.00

Market Cap

4.9M

Sector

Industrials

ML Signal

N/A

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

HOLD

Current Price

$2.59

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIOS
ARTL
Founded
2005
2011
Country
China
United States
Employees
N/A
7
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AIOS
ARTL
Price
$18.00
$2.59
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
520.7K
444.5K
Earning Date
04-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.90
52 Week High
$33.87
$28.60

Technical Indicators

Market Signals
Indicator
AIOS
ARTL
Relative Strength Index (RSI) 69.60 33.65
Support Level $0.48 $1.62
Resistance Level $33.87 $3.67
Average True Range (ATR) 4.85 0.27
MACD 1.18 -0.15
Stochastic Oscillator 52.10 1.73

Price Performance

Historical Comparison
AIOS
ARTL

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: